Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
Clinical trial NCT05555823 · COMPLETED
Trial details
- NCT number
- NCT05555823
- Sponsor
- Atriva Therapeutics GmbH
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-23
- Primary completion
- 2023-07-20
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.